With Genoptix, Novartis Continues Its Diagnostics Build-up
Novartis' $440 million offer for cancer testing services lab Genoptix is another sign of the pharma giant's intent to build a full-blown molecular diagnostics business. The acquisition adds muscle to its existing Molecular Diagnostics unit. Coming just months after GE grabbed up Clarient, it is another example of the value of a specialty cancer services testing operation to an organization looking to bolster channel access to oncologists and pathologists.
You may also be interested in...
Now backed by Roche, can Foundation Medicine continue to innovate in the delivery of molecular information in oncology and outpace the twin threats posed by the commoditization and regulation of genomic data?
Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.
Separate deals with Viiv Healthcare and gene therapy specialist Tocagen illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.